152 related articles for article (PubMed ID: 9417748)
1. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
[TBL] [Abstract][Full Text] [Related]
3. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial).
Preisack MB; Bonan R; Meisner C; Eschenfelder V; Karsch KR
Eur Heart J; 1998 Aug; 19(8):1232-8. PubMed ID: 9740345
[TBL] [Abstract][Full Text] [Related]
4. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Gibson CM; Goel M; Cohen DJ; Piana RN; Deckelbaum LI; Harris KE; King SB
J Am Coll Cardiol; 1998 Jul; 32(1):28-34. PubMed ID: 9669245
[TBL] [Abstract][Full Text] [Related]
5. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
Brack MJ; Ray S; Chauhan A; Fox J; Hubner PJ; Schofield P; Harley A; Gershlick AH
J Am Coll Cardiol; 1995 Oct; 26(4):947-54. PubMed ID: 7560622
[TBL] [Abstract][Full Text] [Related]
6. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
[TBL] [Abstract][Full Text] [Related]
7. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
Jørgensen B; Simonsen S; Endresen K; Forfang K; Vatne K; Hansen J; Webb J; Buller C; Goulet G; Erikssen J; Thaulow E
J Am Coll Cardiol; 2000 Mar; 35(3):592-9. PubMed ID: 10716459
[TBL] [Abstract][Full Text] [Related]
8. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
[TBL] [Abstract][Full Text] [Related]
10. Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Preisack MB; Karsch KR
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S55-8; discussion S59-60. PubMed ID: 8180331
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
Faxon DP; Spiro TE; Minor S; Coté G; Douglas J; Gottlieb R; Califf R; Dorosti K; Topol E; Gordon JB
Circulation; 1994 Aug; 90(2):908-14. PubMed ID: 8044962
[TBL] [Abstract][Full Text] [Related]
12. Minimal heparinization in coronary angioplasty--how much heparin is really warranted?
Kaluski E; Krakover R; Cotter G; Hendler A; Zyssman I; Milovanov O; Blatt A; Zimmerman E; Goldstein E; Nahman V; Vered Z
Am J Cardiol; 2000 Apr; 85(8):953-6. PubMed ID: 10760333
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.
Gimple LW; Herrmann HC; Winniford M; Mammen E
Am J Cardiol; 1999 Jun; 83(11):1524-9. PubMed ID: 10363865
[TBL] [Abstract][Full Text] [Related]
14. Local and systemic delivery of low molecular weight heparin following PTCA: acute results and 6-month follow-up of the initial clinical experience with the porous balloon (PILOT-study). Preliminary Investigation of Local Therapy Using Porous PTCA Balloons.
Oberhoff M; Baumbach A; Hermann T; Diehl C; Maier R; Athanasiadis A; Herdeg C; Bohnet A; Haase KK; Voelker W; Baildon R; Veldhof S; Karsch KR
Cathet Cardiovasc Diagn; 1998 Jul; 44(3):267-74. PubMed ID: 9676794
[TBL] [Abstract][Full Text] [Related]
15. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
Lablanche JM; McFadden EP; Meneveau N; Lusson JR; Bertrand B; Metzger JP; Legrand V; Grollier G; Macaya C; de Bruyne B; Vahanian A; Grentzinger A; Masquet C; Wolf JE; Tobelem G; Fontecave S; Vacheron A; d'Azemar P; Bertrand ME
Circulation; 1997 Nov; 96(10):3396-402. PubMed ID: 9396433
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group.
Emanuelsson H; Beatt KJ; Bagger JP; Balcon R; Heikkilä J; Piessens J; Schaeffer M; Suryapranata H; Foegh M
Circulation; 1995 Mar; 91(6):1689-96. PubMed ID: 7882475
[TBL] [Abstract][Full Text] [Related]
17. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
Faxon DP
J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
[TBL] [Abstract][Full Text] [Related]
18. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
[TBL] [Abstract][Full Text] [Related]
19. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
20. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
